It has been reported that AR expression is positively associated with VEGF-A33, 34, while negatively associated with VEGF-C35, during prostate cancer progression, yet differential metastatic locations of prostate cancer have not been associated with the opposite regulation of VEGF-A and VEGF-C by AR. Here, AR is linked to prostate carcinoma.